FendX Technologies Inc. is a nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens in healthcare and other high traffic touch point venues. The company is developing novel film and spray nano-surface products that repel bacteria and viruses, preventing their replication and spread. The lead product in development, REPELWRAP™ film, is conducting pilot scale-up manufacturing with manufacturing partner Dunmore International to develop intermediate size films for testing and anticipates commercialization in Canada in the second half of 2024.
FendX Technologies is one of the many featured companies slated to present at The Microcap Conference 2024, set for Jan. 30-Feb. 1 at Caesars Atlantic City Hotel and Casino. This three-day conference presented by DealFlow Events features technical programming designed for microcap investors and a presenting company track for pitching and socializing.
History of the company’s formation
FendX Technologies was incorporated in July 2020 and licensed its film nanotechnology IP from McMaster University in February 2021. Licensing of the spray nanotechnology IP followed in May 2023. FendX became a reporting issuer on the CSE effective Jan. 31, 2023, and began trading on the OTCQB and the Frankfurt Stock Exchange on June 2, 2023.
Key Leadership
President, CEO and Director Dr. Carolyn Myers, and COO Andrea Mulder have significant operational experience. Between them, they have launched more than 25 products in the US, Canada and other markets. Dr. Myers has held senior level positions in large-cap pharma companies and been the president of two pharma businesses with a strong track record in leading and growing successful businesses. All FendX fund raising to date has been supported by Canaccord Genuity out of Vancouver Canada, a renowned group who continue to support the company in fund-raising efforts. FendX also has a board with deep experience in finance, capital markets, securities and governance.
A look to the future
The lead product in development, REPELWRAP™ film, is in pilot manufacturing runs at Dunmore. The company anticipates commercializing the film in Canada in the second half of 2024 through distributor partnerships. FendX recently entered a partnership with a nanoparticles manufacturer expert, nanoComposix, to commence intermediate scale-up development of the spray formulation for testing. FendX also announced the development in collaboration with McMaster University of a nano-coating for medical catheters with the goal of reducing bacterial infections and blood clot formation.
Over the next several months the company anticipates news related to the progress of each of these projects as milestones are achieved. Learn more.
Tickets to the inaugural Microcap Conference 2024 are going fast. Reserve your seat now for three days of unsurpassed networking and technical discussions of the microcap sector with some of the best names in the business – institutional investors, finance-focused law firms, venture and private equity fund managers, deal advisors, PIPE funds, brokerage firms, investor relations professionals, accredited retail investors and many more. The conference schedule is also packed with entertainment and exciting activities set against the backdrop of Atlantic City’s bright lights.
Sponsored content, this is a paid promotion
Comments and opinions presented in DealFlow Events publications such as The Microcap Newsletter are solely those of the analysts, corporate executives, and others quoted. They do not represent the opinions of DealFlow Events and DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter.
